Merck quarterly profit beats on strong demand for Keytruda, vaccines

Merck & Co Inc posted a higher-than-expected quarterly profit and raised its full-year earnings forecast on Tuesday, powered by strong demand for its vaccines and cancer immunotherapy Keytruda.